Tumor Marker Heterogeneity in Ovarian Cancer: Clinical Implications of Pretreatment Monitoring of Serum Biomarkers for Recurrence Prediction
Ahmad Alwazzan, Ahmad Badeghiesh, Majid Almansouri, Dahlia Mirdad, Razan Amjad, Zayd Jastaniah, Huda Altoukhi, Rayyan Hasanain, Abdulkareem Fayoumi, Hatim Almarzouki · 2026
Read Tumor Marker Heterogeneity in Ovarian Cancer: Clinical Implications of Pretreatment Monitoring of Serum Biomarkers for Recurrence Prediction by Ahmad Alwazzan, Ahmad Badeghiesh, Majid Almansouri, Dahlia Mirdad, Razan Amjad, Zayd Jastaniah, Huda Altoukhi, Rayyan Hasanain, Abdulkareem Fayoumi, Hatim Almarzouki (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13568730.txt.
Description
Ahmad Alwazzan leads a 2026 retrospective study of 126 ovarian cancer patients asking whether routine blood tumor markers measured before treatment can forecast when cancer will return. Three markers were compared across tumor subtypes in patients treated with major surgery plus chemotherapy.
One marker, CA-125, was raised in about three quarters of patients, far more often than the other two. Surprisingly, raised CA-125 came with a longer time before recurrence in survival analysis, while a third marker carried independent weight in adjusted models. The mixed signals show why single markers mislead, and they argue for combining marker profiles with tumor type when counseling patients about outlook.
Catalog record
| CREATOR | Ahmad Alwazzan, Ahmad Badeghiesh, Majid Almansouri, Dahlia Mirdad, Razan Amjad, Zayd Jastaniah, Huda Altoukhi, Rayyan Hasanain, Abdulkareem Fayoumi, Hatim Almarzouki |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24196 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |